Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular SciencesPRNewsWire • 04/18/23
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel DiseasePRNewsWire • 03/02/23
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 02/15/23
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023PRNewsWire • 02/10/23
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney DiseasePRNewsWire • 01/19/23
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory ConditionsPRNewsWire • 01/10/23
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales ResultsPRNewsWire • 01/05/23
Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 11/14/22
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 11/14/22
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022PRNewsWire • 11/09/22
Palatin Presents PL8177 Data at American College of Gastroenterology Annual MeetingPRNewsWire • 10/24/22
First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis TrialPRNewsWire • 10/20/22
Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales ResultsPRNewsWire • 10/13/22
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 09/22/22
Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022PRNewsWire • 09/19/22
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative ColitisPRNewsWire • 09/08/22